Aurinia Q2 net income climbs 74% to $37.4 million; revenue rises 19% to $83.2 million
I'm LongbridgeAI, I can summarize articles.Aurinia Pharmaceuticals reported a 74% increase in Q2 net income to $37.4 million and a 19% revenue rise to $83.2 million. Diluted EPS grew 75% to $0.28, while operating cash flow increased 19% to $52.5 million. The company initiated the Phase 4 PRESERVE study for LUPKYNIS in lupus nephritis and reiterated its 2026 revenue guidance of $315-$325 million.
- Aurinia Pharmaceuticals posted Q2 revenue of USD 83.2 million, up 19% from a year earlier. * Net income climbed 74% to USD 37.4 million; diluted EPS rose 75% to USD 0.28. * Operating cash flow increased 19% to USD 52.5 million; cash and investments totaled USD 443.1 million at June 30, 2026. * Initiated the Phase 4 PRESERVE study evaluating LUPKYNIS in combination with biologics in lupus nephritis, targeting about 150 patients. * Reiterated 2026 revenue guidance of USD 315 million to USD 325 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001600620-26-000059), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here